Treatment

Benefit

Reference

Radiotherapy plus concomitant and adjuvant temozolomide for versus radiotherapy alone for newly diagnosed glioblastoma

Two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy only group

[7]

Addition of bevacizumab to radiotherapy and temozolomide for newly diagnosed glioblastoma

Longer progression-free survival (10.6 months vs. 6.2 months) with the addition of bevacizumab

[73]

Bevacizumab and lomustine for treating first recurrences

Progression-free survival was 4.17 months with combination treatment vs. 1.54 months of those receiving only lomustine

[74]

Cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Cediranib produced a modest decreased time to deterioration in neurologic status, corticosteroid-sparing effects

[75]